High-Dose Methotrexate Definition
High-dose methotrexate (HDMTX) is defined as any dose exceeding 500 mg/m² 1.
Context-Specific Dosing Ranges
The definition of "high-dose" varies significantly by clinical indication, and understanding these distinctions is critical for safe prescribing:
Oncology Applications
For primary central nervous system lymphoma (PCNSL), high-dose methotrexate typically refers to doses of at least 3 g/m² administered as a rapid infusion over 2-4 hours 2. The evidence supports that doses in the 3-8 g/m² range are commonly used, with some centers preferring 8 g/m² for improved complete response rates (68.29% vs 43.75% at 3.5 g/m²) and progression-free survival 3. However, doses of 3-5 g/m² demonstrate similar efficacy with lower toxicity, particularly important for older patients or those with comorbidities 4.
For osteosarcoma, the standard high-dose regimen is 12 g/m² administered as a starting dose, with potential escalation to 15 g/m² if peak serum concentrations don't reach 1,000 micromolar 5. This represents the upper end of HDMTX dosing and requires meticulous monitoring with leucovorin rescue.
Rheumatologic and Dermatologic Applications
In stark contrast, for rheumatoid arthritis and psoriasis, what clinicians consider "high-dose" is dramatically different. The maximum recommended weekly dose is 20-30 mg/week 6, 7. This is NOT considered high-dose methotrexate by oncology standards - it falls well below the 500 mg/m² threshold. The FDA label explicitly states that total weekly doses should not ordinarily exceed 30 mg 8.
Critical Distinction: Low-Dose vs High-Dose
Low-dose methotrexate is defined as <25 mg per week and works primarily through immunosuppressive effects on lymphoid cells 7. This is the mechanism relevant for inflammatory conditions.
High-dose methotrexate (>500 mg/m²) requires completely different supportive care including:
- High-volume hydration
- Urinary alkalinization
- Leucovorin rescue starting 24 hours post-infusion
- Therapeutic drug monitoring of serum methotrexate levels
- Potential glucarpidase availability for delayed elimination 5, 1
Common Pitfall
The most critical error is confusing the dosing paradigms between oncology and rheumatology/dermatology. A rheumatologist's "high dose" of 25-30 mg weekly is actually low-dose by oncology standards and requires fundamentally different monitoring and supportive care protocols. When prescribing or discussing methotrexate, always clarify the clinical indication as this determines whether you're operating in the low-dose (<25 mg/week) or true high-dose (>500 mg/m²) range.